ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
In the gynecologic expansion cohort of the first-in-human, phase 1 MYTHIC trial, the combination of lunresertib (a PKMYT1 inhibitor) and camonsertib (an ATR inhibitor) produced durable objective responses in heavily…
✓ Primary source cited
Last reviewed
Clinical Trials
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
Participants age 18 Years and older with Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-10-20
Regulatory status by jurisdiction
Country or region not specified
Status
Investigational
Last verified
2026-10-20
Cancer-type scope for this record is not yet recorded.
Participants age 18 Years and older with Endometrial Carcinoma, Neoplasms, Endometrial who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-10-20
Regulatory status by jurisdiction
Country or region not specified
Status
Investigational
Last verified
2026-10-20
Cancer-type scope for this record is not yet recorded.
Participants age 18 Years and older with Endometrial Neoplasms, Endometrial Cancer who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-10-08
Regulatory status by jurisdiction
Country or region not specified
Status
Investigational
Last verified
2026-10-08
Cancer-type scope for this record is not yet recorded.
Participants age 18 Years and older with Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-09-22
Regulatory status by jurisdiction
Country or region not specified
Status
Investigational
Last verified
2026-09-22
Cancer-type scope for this record is not yet recorded.
Participants age 18 Years and older with Endometrial Cancer, Recurrent or Progressive Endometrial Cancer who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-09-09
Regulatory status by jurisdiction
Country or region not specified
Status
Investigational
Last verified
2026-09-09
Cancer-type scope for this record is not yet recorded.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.